Positive efficacy result for Immutep’s 'efti' in combination with MSD's KEYTRUDA

October 23, 2023 Australian Biotech

This is a preview of subscriber content

Subscribe now to continue reading.

Australian company Immutep (ASX:IMM) has announced positive data from a trial of its LAG-3 immunotherapy, eftilagimod alpha, in combination with MSD's KEYTRUDA (pembrolizumab). …

Subscribe now to continue reading.

Latest Video

Australia has 'all the ingredients' but has to decide what kind of health system it wants
November 26, 2025 - BioPharma
Updated asthma guidelines warn against ‘blue puffer only’ treatment as deaths remain stubbornly high
November 26, 2025 - Latest News
An interview that reminds us of the missing discussion in Australia
November 27, 2025 - Latest News
The US and UK edging closer to an agreement on pharmaceutical pricing
November 26, 2025 - Latest News
Australian melanoma oncologist awarded inaugural Marie Krogh Prize for Young Women in Science
November 26, 2025 - Latest News

Positive efficacy result for Immutep’s 'efti' in combination with MSD's KEYTRUDA

This is a preview of subscriber content

Latest Video

Most Read

Australia has 'all the ingredients' but has to decide what kind of health system it wants

Updated asthma guidelines warn against ‘blue puffer only’ treatment as deaths remain stubbornly high

An interview that reminds us of the missing discussion in Australia

The US and UK edging closer to an agreement on pharmaceutical pricing

Australian melanoma oncologist awarded inaugural Marie Krogh Prize for Young Women in Science

New Stories

Pharmac announces 90-day dispensed quantities of HIV medicines

Landmark report warns Australia’s hospital pharmacy system is at an 'inflection point'

Australia releases first national estimate of women living with metastatic breast cancer

Imugene and JW Therapeutics join forces on first-in-class combination for solid tumours

Algorae Pharmaceuticals secures new supply of chemotherapy for Australia through Dr Reddy’s partnership

An interview that reminds us of the missing discussion in Australia

Neurizon Therapeutics entering 'a promising new horizon” as ALS program advances

Sign In

Positive efficacy result for Immutep’s 'efti' in combination with MSD's KEYTRUDA

This is a preview of subscriber content

Latest Video

Most Read

Australia has 'all the ingredients' but has to decide what kind of health system it wants

Updated asthma guidelines warn against ‘blue puffer only’ treatment as deaths remain stubbornly high

An interview that reminds us of the missing discussion in Australia

The US and UK edging closer to an agreement on pharmaceutical pricing

Australian melanoma oncologist awarded inaugural Marie Krogh Prize for Young Women in Science

Follow Us

New Stories

Pharmac announces 90-day dispensed quantities of HIV medicines

Landmark report warns Australia’s hospital pharmacy system is at an 'inflection point'

Australia releases first national estimate of women living with metastatic breast cancer

Imugene and JW Therapeutics join forces on first-in-class combination for solid tumours

Algorae Pharmaceuticals secures new supply of chemotherapy for Australia through Dr Reddy’s partnership

An interview that reminds us of the missing discussion in Australia

Neurizon Therapeutics entering 'a promising new horizon” as ALS program advances